Clinical Trial Results:
Open-label, multicenter, multinational, interventional clinical trial to assess effectiveness and safety of the extemporaneous combination of nebivolol and zofenopril calcium in grade 1 to 2 hypertensive patients versus each monotherapy
Summary
|
|
EudraCT number |
2020-002340-23 |
Trial protocol |
IT |
Global end of trial date |
22 Dec 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Jan 2023
|
First version publication date |
07 Jan 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MEIN/19/ZoNe-HYP/001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05257148 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Menarini International Operation Luxembourg SA
|
||
Sponsor organisation address |
1, Avenue de la Gare, Luxembourg, Luxembourg, L-1611
|
||
Public contact |
Clinical Operation Director, Menarini, +39 055568091, pfabrizzi@menarini.it
|
||
Scientific contact |
Clinical Operation Director, Menarini, +39 055568091, pfabrizzi@menarini.it
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 May 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
22 Dec 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Dec 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the antihypertensive effect of the extemporaneous combination of nebivolol 5 mg and zofenopril calcium 30 mg in lowering sitting diastolic blood pressure (DBP) after 8 weeks of treatment, in patients with uncontrolled blood pressure (BP) who were previously treated with nebivolol or zofenopril calcium monotherapies for at least 4 weeks
|
||
Protection of trial subjects |
The study was conducted in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCP), including the archiving of essential documents as well as the ethical principles of the Declaration of Helsinki.
|
||
Background therapy |
No Background Therapy | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
08 Mar 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 267
|
||
Country: Number of subjects enrolled |
Italy: 16
|
||
Worldwide total number of subjects |
283
|
||
EEA total number of subjects |
283
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
283
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Study started on 26 May 2021 and terminated on 22 December 2021 296 patients were screened for the study. 283 patients entered the run-in period and were assigned for monotherapy to Nebivolol (NEB) 5 mg or Zofenopril (ZOF) 30 mg. Of the 269 completed patients in monotherapy, 246 were assigned to combination therapy and 238 competed the study | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
296 patients male and female Caucasian uncontrolled hypertensive patients ≥ 18 and < 65 years of age on monotherapy either with ACE-i or BBs since at least 1 month and with mean sitting SBP ≥ 140 mmHg and ≤ 179 mmHg and / or mean sitting DBP ≥ 90 mmHg and ≤ 109 mmHg, were screened. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Run-in Period
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
Open-label study, not blinded
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Zofenopril 30 mg | ||||||||||||||||||
Arm description |
Patients in therapy with ACE-i, were assigned to monotherapy with ZOFENOPRIL 30 mg for 4 weeks | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Zofenopril 30 mg
|
||||||||||||||||||
Investigational medicinal product code |
Zofenopril calcium
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily
|
||||||||||||||||||
Arm title
|
Nebivolol 5 mg | ||||||||||||||||||
Arm description |
Patients in therapy with Beta Blockers, were assigned to monotherapy with Nebivolol 5 mg for 4 weeks | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Nebivolol 5mg
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Assessment
|
||||||||||||||||||
Is this the baseline period? |
Yes [1] | ||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
Open-label study, not blinded
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
Combination Therapy Zofenopril 30mg/Nebivolol 5mg | ||||||||||||||||||
Arm description |
During the assessment period of 8 weeks, the eligible patients (uncontrolled hypertension with sitting BP of SBP/DBP > 130/80 mmHg, who tolerated the treatment and whose adherence to the therapies ranged from 80% to 120%) received a combination of NEB 5 mg and ZOF 30 mg to be taken orally once daily. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Nebivolol 5mg
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily
|
||||||||||||||||||
Investigational medicinal product name |
Zofenopril 30 mg
|
||||||||||||||||||
Investigational medicinal product code |
Zofenopril calcium
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily
|
||||||||||||||||||
Notes [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: Period 1 is the Run-in period. The objective of the study is to evaluate the effectiveness and safety of the combination therapy (Zofenopril/Nebivolol) versus the monotherapy. Hence the baseline period starts on Period 2, with the assessment of blood pressure after the run-in period and the intake of the combination therapy. |
|||||||||||||||||||
|
|||||||||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 283 patients are enrolled patients that are included in the Run-in period (Period 1). Period 1 is not the baseline period. Patients [3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: After the Run-in Period, Patients with controlled BP (sitting SBP / DBP ≤ 130/80 mmHg) at Week 0 (Visit 2), patients with uncontrolled BP (sitting SBP / DBP > 130/80 mmHg) whose adherence to the treatment was not included from 80% to 120%, or patients who could not tolerate one of the mono therapies were discontinued from the study and excluded from the Assessment Period (23 patients in total) |
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
Assessment
|
|||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Zofenopril 30 mg
|
||
Reporting group description |
Patients in therapy with ACE-i, were assigned to monotherapy with ZOFENOPRIL 30 mg for 4 weeks | ||
Reporting group title |
Nebivolol 5 mg
|
||
Reporting group description |
Patients in therapy with Beta Blockers, were assigned to monotherapy with Nebivolol 5 mg for 4 weeks | ||
Reporting group title |
Combination Therapy Zofenopril 30mg/Nebivolol 5mg
|
||
Reporting group description |
During the assessment period of 8 weeks, the eligible patients (uncontrolled hypertension with sitting BP of SBP/DBP > 130/80 mmHg, who tolerated the treatment and whose adherence to the therapies ranged from 80% to 120%) received a combination of NEB 5 mg and ZOF 30 mg to be taken orally once daily. | ||
Subject analysis set title |
Intention to treat population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
all patients who were enrolled and received at least 1 dose of study drug (combination therapy) and
have at least 1 post baseline safety assessment.
|
|
|||||||||||||
End point title |
Change in mean sitting DBP | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
8 weeks of combination therapy treatment. From study visit 2 to study visit 3.
|
||||||||||||
|
|||||||||||||
Notes [1] - Only 241 patient have valid SBP measurement at baseline. Values collected here are baseline ones [2] - Values collected here are SBP measurement at the end of the study |
|||||||||||||
Statistical analysis title |
Monotherapy vs Combination in DBP after 8 weeks | ||||||||||||
Statistical analysis description |
Change from Baseline in the Diastolic Blood Pressure (DBP).
|
||||||||||||
Comparison groups |
Combination Therapy Zofenopril 30mg/Nebivolol 5mg v Intention to treat population
|
||||||||||||
Number of subjects included in analysis |
482
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
From Informed Consent signed to final visit
|
||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||
Dictionary version |
24.1
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
Combination Therapy Zofenopril 30mg/Nebivolo l 5mg
|
||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Note that due to technical limits in the portal the statistical analysis reports 482 patients included in the analysis and not 241 as they effectively are. 482 are indeed the 241 data collected before and the 241 after combined therapy intake |